What is GI Windows?
Headquartered in Westwood, Massachusetts, GI Windows operates at the intersection of surgical innovation and patient-centric care. Since its inception in 2012, the company has focused exclusively on the engineering of anastomoses technology—a critical component in gastrointestinal surgery. By developing devices that facilitate seamless tissue connection, GI Windows addresses significant unmet needs in the surgical market, aiming to reduce recovery times and improve long-term patient outcomes. The company's market position is defined by its specialized focus on high-barrier-to-entry medical devices, leveraging deep technical expertise to disrupt traditional surgical methodologies.
How much funding has GI Windows raised?
GI Windows has raised a total of $53.4M across 2 funding rounds:
Series A
$16.4M
Series B
$37M
Series A (2020): $16.4M with participation from Johnson & Johnson Innovation – JJDC, Inc., GT Healthcare Capital Partners, JC Investco, and Sonder Capital
Series B (2024): $37M led by Orlando Health, Rex Health Ventures, and JCInvestco
Key Investors in GI Windows
Orlando Health
Orlando Health is a comprehensive, not-for-profit healthcare organization that manages an extensive network of hospitals and outpatient facilities, providing strategic clinical insights to emerging medical technologies.
Rex Health Ventures
Rex Health Ventures is the investment arm of UNC REX Healthcare, dedicated to supporting early-stage healthcare entrepreneurs and fostering breakthrough innovations in patient care.
GT Healthcare Capital Partners
GT Healthcare Capital Partners is a global venture capital firm specializing in high-growth healthcare investments, providing the financial backing necessary for international market expansion.
What's next for GI Windows?
With the successful closure of its latest financing round, GI Windows is poised to enter a critical phase of operational scaling and clinical validation. The strategic nature of this investment suggests a focus on accelerating the commercialization of its core technology, potentially expanding its footprint within major hospital networks and surgical centers. As the company moves forward, the integration of its devices into standard clinical workflows will be paramount. Investors are likely looking for robust clinical data to support broader adoption, while the company's leadership will focus on optimizing manufacturing processes and navigating the regulatory pathways required for global market entry. This capital provides the necessary runway to transition from a development-stage entity to a commercial-scale medical device leader, setting the stage for potential long-term value creation in the gastrointestinal health space.
See full GI Windows company page
